Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
The ongoing Phase 1 trial assesses safety, tolerability and preliminary signs of efficacy across escalating dose levels.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Anixa Biosciences (ANIX) announced that ovarian cancer CAR-T therapy inventor Jose Conejo-Garcia will deliver a conference keynote on November 3, 2026. The Ovarian Cancer Midwest Focus Conference, hosted by Mayo Clinic and University of Minnesota, runs November 2–3 in Rochester, Minnesota.
Anixa's lira-cel, a therapy using modified immune cells, is being evaluated in an ongoing Phase 1 trial with Moffitt Cancer Center. No dose-limiting toxicities have been observed to date. Four patients have surpassed one year of survival following treatment, including one beyond two years. The first patient treated at the highest dose to date exhibited stable disease 90 days after treatment.
Positive
- Minor pointNo dose-limiting toxicities have been observed to date in the ongoing Phase 1 trial.
- Minor pointFour patients surpassed one year of survival following treatment, including one beyond two years.
- Minor pointStable disease 90 days after treatment was observed in the first patient at the highest dose to date.
Negative
- None.
Key Figures
- Trial phase
- Phase 1
- Ovarian cancer CAR-T trial
- Patients surviving beyond one year
- 4 patients
- Following treatment
- Survival beyond two years
- 1 patient
- Following treatment
- Stable disease assessment
- 90 days
- First patient treated at the highest dose to date
- Dose-limiting toxicities observed
- 0
- Ongoing trial to date
Historical Context
-
Reported the same 90-day stable-disease assessment in the ongoing ovarian CAR-T trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
car-t medical
follicle-stimulating hormone receptor medical
dose-limiting toxicities medical
stable disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference
Dr. Conejo-Garcia's presentation is titled "Closing in: Cracking Ovarian Cancer's Resistance to Immunotherapy." He is Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine.
"Dr. Conejo-Garcia's research into the immune biology of ovarian cancer led to the invention of the technology underlying lira-cel, our ovarian cancer CAR-T therapy," said Dr. Amit Kumar, Chairman and CEO of Anixa. "We are pleased that he will share his insights with the ovarian cancer research community at this conference."
Anixa's ovarian cancer CAR-T therapy, liraltagene autoleucel, or lira-cel, is being evaluated in an ongoing Phase 1 clinical trial in collaboration with Moffitt Cancer Center. The investigational therapy uses chimeric endocrine receptor-T cell technology designed to target the follicle-stimulating hormone receptor, which is expressed on ovarian cancer cells but has limited expression in healthy tissues. The trial is designed to assess safety, tolerability, and preliminary signs of efficacy across escalating dose levels. To date, no dose-limiting toxicities have been observed, and four patients have surpassed one year of survival following treatment, with one of them having survived beyond two years. In addition, the first patient treated at the highest dose to date exhibited stable disease 90 days after treatment.
Presentation details:
Event: 2026 Ovarian Cancer Midwest Focus Conference
Speaker: Jose Conejo-Garcia, MD, PhD
Topic: Closing in: Cracking Ovarian Cancer's Resistance to Immunotherapy
Location: Marriott Hotel,
Presentation date and time: 9:00 AM CT, Tuesday, November 3, 2026
The Ovarian Cancer Midwest Focus Conference brings together researchers, clinicians, patient advocates and others affected by ovarian cancer to share advances in research and care. Established at the University of
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ovarian-cancer-car-t-therapy-inventor-to-deliver-keynote-at-ovarian-cancer-midwest-focus-conference-302906322.html
SOURCE Anixa Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What results has Anixa reported for its ovarian cancer lira-cel trial?
No dose-limiting toxicities have been observed to date, and four patients have surpassed one year of survival following treatment, including one beyond two years. The first patient treated at the highest dose to date exhibited stable disease 90 days after treatment. The Phase 1 trial remains ongoing.
When will Anixa's ovarian cancer CAR-T inventor give his conference keynote?
Jose Conejo-Garcia will present at 9:00 AM CT on November 3, 2026, at the Marriott Hotel in Rochester, Minnesota. His keynote at the Ovarian Cancer Midwest Focus Conference is titled “Closing in: Cracking Ovarian Cancer's Resistance to Immunotherapy.”
What is Anixa's Phase 1 lira-cel trial designed to assess?
The trial is designed to assess safety, tolerability and preliminary signs of efficacy across escalating dose levels. It is being conducted in collaboration with Moffitt Cancer Center.